News and Trends 29 May 2015
Poxel is Looking towards Japan’s Lucrative Diabetes Market
Poxel, the French company that made a €27M IPO last February, announced the successful conclusion of a phase 1 clinical trial in Japanese subjects with Imeglimin, its lead drug candidate. Imeglimin has already completed phase 2 clinical trials in type 2 diabetes patients in the US and EU and is ready for Phase III. This […]